Primary Care Diabetes
Volume 2, Issue 4 , Pages 167-173 , December 2008

Optimizing diabetes management through glucose profiling: A case-based approach

  • Dan A. Streja

      Affiliations

    • Corresponding Author InformationCorrespondence address: 7345 Medical Center Drive, West Hills, CA 91307, United States. Tel.: +1 818 347 2921.

Received 21 May 2007 ,Revised 21 May 2008 ,Accepted 26 June 2008.

References 

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053
  2. Centers for Disease Control and Prevention, National diabetes fact sheet. United States, 2005, available from http://www.diabetes.org/diabetes-statistics.jsp (accessed October 6, 2005).
  3. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann. Intern. Med. 1996;124(1 Pt 2):90–96
  4. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–2569
  6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  7. Skyler JS. Evidence for glycated hemoglobin targets from the diabetes control and complications trial. Endocr. Pract. 2002;8(Suppl. 1):27–30
  8. American Diabetes Association . Standards of medical care in diabetes–2006. Diabetes Care. 2006;29(Suppl. 1):S4–S42
  9. L’Agence Nationale d’Accréditation et d’Evaluation en Santé . Follow-up of the type 2 diabetic patient excluding follow-up of complications. Recommendations of ANAES. Diabetes Metab. 1999;25(Suppl. 2):1–64
  10. European Diabetes Policy Group 1999 . A desktop guide to Type 2 diabetes mellitus. Diabet. Med. 1999;16(9):716–730
  11. American Association of Clinical Endocrinologists, American College of Endocrinology . Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management–2002 update. Endocr. Pract. 2002;8(Suppl. 1):40–82
  12. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Targets for glycemic control. Can. J. Diab. 2003;27(Suppl. 2):S18–S20
  13. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968–983
  14. Hempe JM, Gomez R, McCarter RJ, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J. Diabetes Complications. 2002;16(5):313–320
  15. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275–278
  16. Hillman N, Herranz L, Grande C, Vaquero PM, Pallardo LF. What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes?. Diabet. Med. 2004;21(5):468–470
  17. Nichols JH. What is accuracy and how close must the agreement be?. Diabetes Technol. Ther. 2005;7(3):558–562
  18. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  19. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet. Med. 2005;22(6):749–755
  20. Bouma M, Dekker JH, de Sonnaville JJ, et al. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes?. Diabetes Care. 1999;22(6):904–907
  21. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care. 2002;25(4):737–741
  22. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20(12):1822–1826
  23. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881–885
  24. Colette C, Ginet C, Boegner C, et al. Dichotomous responses of inter and postprandial hyperglycaemia to short-term calorie restriction in patients with type 2 diabetes. Eur. J. Clin. Invest. 2005;35(4):259–264
  25. Rodriguez BL, Lau N, Burchfiel CM, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care. 1999;22(8):1262–1265
  26. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22(6):920–924
  27. Qiao Q, Pyorala K, Pyorala M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur. Heart J. 2002;23(16):1267–1275
  28. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926–931
  29. Hanefeld M, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39(12):1577–1583
  30. Sievers ML, Bennett PH, Nelson RG. Effect of glycemia on mortality in Pima Indians with type 2 diabetes. Diabetes. 1999;48(4):896–902
  31. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care. 1998;21(8):1236–1239
  32. Pearson J, Bergenstal R. Fine-tuning control: pattern management versus supplementation. View 1. Pattern management: an essential component of effective insulin management. Diabetes Spectrum. 2001;14(2):75–78
  33. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 1995;28:103–117
  34. Welschen LMC, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care. 2005;28(6):1510–1517
  35. Langer O, Rodriguez DA, Xenakis EMJ, McFarland MB, Berkus MD, Arrendondo F. Intensified versus conventional management of gestational diabetes. Am. J. Obstet. Gynecol. 1994;170(4):1036–1046
  36. Jovanovic L. American Diabetes Association's Fourth International Workshop-Conference on Gestational Diabetes Mellitus: summary and discussion. Therapeutic interventions. Diabetes Care. 1998;21(Suppl. 2):B131–B137
  37. American College of Obstetricians and Gynecologists, ACOG Practice Bulletin, Clinical management guidelines for obstetrician–gynecologists, Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994), Gestational diabetes, Obstet. Gynecol. 98 (3) (2001) 525–538.
  38. American Diabetes Association . Gestational diabetes mellitus. Diabetes Care. 2004;27(Suppl. 1):S88–S90
  39. McElduff A, Cheung NW, McIntyre HD, et al. The Australasian Diabetes in Pregnancy Society consensus guidelines for the management of type 1 and type 2 diabetes in relation to pregnancy. Med. J. Aust. 2005;183(7):373–377

PII: S1751-9918(08)00071-5

doi: 10.1016/j.pcd.2008.06.004

Primary Care Diabetes
Volume 2, Issue 4 , Pages 167-173 , December 2008

Article Tools

* Image Usage & Resolution